Omega Diagnostics Share Discussion Threads

[davr0s] 03/12/2018 07:34

The key question is has it met previously indicated low expectations - we'll find out in the coming days

[hyperboreus] 03/12/2018 07:16

Underwhelming results as I expected and David Evans at his flowery worst with his outlook statement:

"Our short-term outlook is dominated by our efforts to realise value for Shareholders whilst at the same time successfully accelerating our efforts to commercialise our CD4 offering. The challenges are not inconsequential but I remain confident that in those areas where we can control our own destiny that we will succeed in delivering our objectives. In those areas where we are not masters of our own destiny then, by definition, the outcome will always be less certain. I believe it is best for our statement to reflect that reality as it stands today. Rest assured we will continue to work towards achieving success for all our Stakeholders."

Of even more concern, Bank overdraft at the period end of £0.45m (2017: cash of £2.42m) and yet:

'The commissioning of a new 35,000 sq. ft facility is proceeding to plan with an expected move during the middle of the next calendar year. The upgraded facility underpins our view that the food intolerance division offers longer term growth opportunity, particularly in the US and China, and the Board continues to explore how best to realise value from this division given its stage in its current life-cycle.'

[bomber13] 23/11/2018 18:09

Immunodiagnostics have just issued their rather dull , but in-line , interims for the 6 months to end September , and here is what they say about allergy assays -

" Additionally, during H1 we successfully CE marked the first 59 Allergy assays obtained from our partner Omega Diagnostics. We expect to see the first opportunistic sales from this panel during H2. "

This seems to be exactly in line with Omega's trading update in mid-October , which confirmed that they had received their first few orders from IDS .

[hyperboreus] 20/11/2018 13:03

Quality Validation Manager required:

[gwr7] 20/11/2018 08:04

I suspect anyone who was in love traded in for a newer model last year.

[buywell3] 18/11/2018 01:12

This has been a long and hard road for some

ODX has made many mistakes

Assumptions of what is going to sell or what is needed have not been met by market requirements

Falling in love with a share can led to heartbreak and wallet burn

[barrywhit] 09/11/2018 14:55

ODX Still hiring...

We’re looking for a Senior Protein Purification Scientist based at our site in Alva, just outside of Stirling, Scotland.

[bomber13] 08/11/2018 17:34

I am seriously hoping for an upgrade to expectations for the full year with the interims on 3rd December , as per the tone of the early October update . This period has also witnessed continued buying support from Oryx , preceded by Richard Sneller reaching 20% . Interestingly , the latter's 4 year average purchase price is probably only around or just below current levels , so he , for one , must feel there is still plenty to shoot for .I also hope that they will host their third investor evening of the year in order to keep the spirit of shareholder friendly openness alive and kicking .For what it is worth , the charts are in agreement . They now show a clear reverse head and shoulders , a break of the longer term downtrend , and a golden cross on the 50 and 200 day moving averages .

[barrywhit] 08/11/2018 16:45

The sellers have come out Leeds, but a good rise in share price ...

[leedslad001] 08/11/2018 13:43

May be a nice Christmas present for us in the pipeline

[hyperboreus] 08/11/2018 12:18

Looking perky! 😛

[hyperboreus] 02/11/2018 15:51

I was beginning to think the same barry but 2 x 50,000 sells this afternoon would suggest otherwise, not wishing to put the mockers on things here but I do agree with rivaldo that the current share price of 16.5p is remarkable in the current market given where it was at the end of June.

Interesting to note that on further investigation one of the 3 vacancies currently advertised is for a Product Marketing Manager for the Food Intolerance Business based in Littleport Cambs

Food Intolerance Testing (FIT) will be responsible for managing marketing programs and strategies for the Food Intolerance product offering of Cambridge Nutritional Sciences (CNS). He/She will work closely with Sales & Marketing, R&D, Regulatory, Omega global distributor network and other sales outlets to ensure the Food Intolerance product portfolio is correctly positioned in the diagnostic marketplace for growth and sustainability.

That possibly put the nail in the coffin of my theory that they are likely to flog it off anytime soon but we shall see!

[barrywhit] 02/11/2018 09:28

Looks like the main seller has finished, back to normal trading hopefully...

[rivaldo] 02/11/2018 09:03

Breaking upwards now with buying at 16.9p today. Very encouraging performance given recent general market sentiment!

[arthur_lame_stocks] 31/10/2018 15:37

I doubled up my holdings here recently, I believe these are worth 30p in time and there is not much downside from here due to the profits of Food Intolerance.

The major shareholders are clearly looking for the value to come out so I don't reckon it'll be an awfully long wait.

[barrywhit] 31/10/2018 15:35

This is an exciting time as we expand and grow, improving human health & well-being through innovative diagnostic tests. We’re looking for enthusiastic people to join our Production, Marketing and Quality teams.

[barrywhit] 29/10/2018 17:31

Feels like only yesterday we were preparing for Medica 2017. Now we're just 2 weeks away from #Medica2018!

Drop by our booth 3AC02-1 to find out more information on our range of health & well-being tests, and our groundbreaking VISITECT CD4 test.

We should be getting an update on the New 350 test Field Trials any time now....

[barrywhit] 26/10/2018 16:29

Looks like we still have a buyer. and the bid has increased.....

[barrywhit] 22/10/2018 09:54

Very comprehensive read, still looks good for ODX especially with the new IMPROVED CD4 test....there is a lot of value in the company when all is bought to market...

[hyperboreus] 21/10/2018 17:55

Interesting article for anyone prepared to trawl through it, surprising news(for me that is) regarding CD4 forecast testing projections:

[hyperboreus] 21/10/2018 14:12

As we all know in the last update Colin King, CEO of Omega commented:

"We are making great progress implementing our revised strategic direction and the narrower focus is already starting to deliver in our three key areas. Overall, we believe the actions we are taking will ultimately deliver shareholder value both in the short and long term."

Normally short term in my opinion refers to a period of less than 1 year therefore I feel that the board must have something else in mind regarding one of Omega's assets and logically you would think that has to be something to do with the Food Intolerance
business.

Final comment, interims due on 3 December and exactly one week later the first tranche of options with an exercise price of 19p expire that were granted on 10 December 2008 to Messrs Evans, Shepherd and Harbinson expire!

[bomber13] 19/10/2018 18:29

Good spot Barrywhit , there were 500/- shares traded on Wednesday , which I suspect was Oryx giving over 15p for stock . It is hugely encouraging that Messrs Sneller and Miller are still paying up for stock having taken Liontrust out at under 10p in late April .

We are currently trading on an EV/sales of around 2x with revenues at rock bottom levels , and nothing from CD4 and Allersys . If you believe that the company will achieve its 3 - 5 year revenue targets in each of the three business segments , as per the August presentation , then we are trading on a pro-forma EV/Sales of 0.45x . For comparison , the big daddy of diagnostics , Thermo Fisher , currently trades on an EV/Sales of over 4x .

In my view , the half-term trading update 10 days ago seemed to set the market up for an upgrade from Finncap with the interims on 3rd December .

Here's hoping .

[arthur_lame_stocks] 19/10/2018 18:06

I didn't say imminently, but if food intolerance really has returned to growth I can see that going before too long, some cash being returned and some being kept back for the development of CD4 and the allergy business and then those eventually being sold too.

[barrywhit] 19/10/2018 16:54

A-L-S, Too soon for corporate action in my opinion for a reasonable return, 18 months down the line and we could see a very good return....

[arthur_lame_stocks] 19/10/2018 16:43

I expect corporate action here before too long. Chris Mills is known to be activist and I still believe the fundamental value of the share is some way higher than the current price.